The rate of use of phosphodiesterase-5 PDE5 inhibitor without physician recommendation and the faults of using medication in patients with erectile dysfunction

Year 2011, Volume: 6 Issue: 2, 26 - 31, 01.05.2011

Zeki Bayraktar İhsan Atun

Abstract

Objective: In this study, we evaluated the rate of use of phosphodiesterase-5 PDE5 inhibitor without physician recommendation and the faults of using medication in patients with erectile dysfunction ED .Materials and methods: A total of 310 patients with ED were evaluated. The patients were divided into subgroups according to age and education level. In all groups, the rate of use of PDE5 inhibitor without physician recommendation and the rate of use of PDE5 inhibitor together with nitrate and alpha-blocker were determined. The rates between the groups were compared statistically by package program MedCalc Software v11.5.1 . Results: The age of the patients ranged between 38-73 57.4 ± 7.9 . The rate of use of PDE5 inhibitor without physician recommendation was 26.4% 82/310 in general, 20.7% 45/217 in primary school graduates, 39.7% 37/93 in high school/university graduates, 31.1% in below 60 years of age 57/183 and 19.6% in over 60 years of age 25/127 . The rate of use of PDE5 inhibitor was significantly higher in high school/university graduates p = 0.002 . But, there was no significant difference in age-related groups p = 0.053 . The use of PDE5 inhibitor together with nitrate and alpha-blocker was 2.9% and 3.5%, respectively. These rates were significantly higher in high school/university graduates p = 0.016, p = 0.014 . However, there were no significant difference between age-related groups p = 0.832, P = 0359 . Conclusion: The rate of use of PDE5 inhibitor without physician recommendation was found significantly high in patients with ED. In addition, these patients have significant faults in medication use

Keywords

Erectile dysfunction , PDE5 inhibitor , contraindication

Erektil disfonksiyonlu hastalarda hekim önerisi olmaksızın fosfodiesteraz-5 PDE5 inhibitörü kullanım oranı ve ilaç kullanım hataları

Abstract

Amaç: Bu çalışma ile erektil disfonksiyonlu ED hastalarda, hekim önerisi olmaksızın fosfodiesteraz-5 PDE5 inhibitörü kullanan hasta oranını ve bu hastalardaki hatalı ilaç kullanım özelliklerini araştırdık. Gereç ve yöntem: Toplam 310 ED’li hasta değerlendirildi. Hastalar, eğitim durumuna ve yaşa bağlı olarak alt gruplara ayrıldı. Tüm gruplarda, hekim tavsiyesi olmaksızın PDE-5 inhibitörü kullanan hasta oranı ve PDE-5 inhibitörü ile birlikte nitrat ve alfa bloker kullanan hasta oranı tespit edildi. Gruplar arasındaki oranlar, istatistiksel olarak paket programla MedCalc Software v11.5.1 karşılaştırıldı. Bulgular: Hastaların yaş aralığı 38 ile 73 arasında idi 57.4±7.9 . Hekim önerisi olmaksızın kendi kendine PDE-5 inhibitörü kullanan hasta oranı genel olarak %26.4 82/310 , ilköğretim mezunlarında %20.7 45/217 , lise/üniversite mezunlarında %39.7 37/93 , 60 yaş altı hastalarda %31.1 57/183 ve 60 yaş üzeri hastalarda %19.6 25/127 idi. Kendi kendine PDE-5 inhibitörü kullanım oranı lise/üniversite mezunlarında anlamlı düzeyde yüksekti p=0.002 . Ancak, yaşa bağlı gruplarda anlamlı bir fark yoktu p=0.053 . PDE5 inhibitörü ile birlikte nitrat ve alfa-bloker kullanan hasta oranı, sırasıyla %2.9 ve %3.5 idi. Bu oranlar, lise/üniversite mezunlarında anlamlı düzeyde yüksekti p=0.016, p=0.014 . Buna karşı, yaşa bağlı gruplar arasında anlamlı bir fark yoktu p=0.832, p=0.359 . Sonuç: ED hastalarında hekim önerisi olmaksızın PDE5 inhibitör kullanım oranı anlamlı derecede yüksek bulunmuştur. Ayrıca, bu hastalarda önemli oranda ilaç kullanım hataları bulunmaktadır

Keywords

Erektil disfonksiyon , PDE-5 inhibitörü , kontrendikasyon

References

• Padma-Nathan H, Steers WD, Wicker PA. Efficacy and sa- fety of oral sildenafil in the treatment of erectile dysfunc- tion: a double-blind, placebo-controlled study of 329 pati- ents. Sildenafil Study Group. Int J Clin Pract; 52: 375-79, 1998.
• Steers WD. Viagra-after one year. Urology; 54: 12-17, 1999
• Symonds T, Coyne KS, Margolis MK, et al. The Ability of the General Male Public to Assess Their Suitability to Take 50-mg Sildenafil: An Assessment of the Comprehension of Patient Information Materials via Internet Survey. J Sex Med 2011 Apr 7. doi: 10.1111/j.1743-6109.2011.02263.x.
• Eryildirim B, Aktas A, Kuyumcuoglu U, et al. The effective- ness of sildenafil citrate in patients with erectile dysfuncti- on and lower urinary system symptoms and the significan- ce of asymptomatic inflammatory prostatitis. Int J Impot Res; Nov-Dec;22(6):349-54, 2010.
• Ozgur BC, Gonenc F, Yazicioglu AH. Sildenafil or varde- nafil nonresponders erectile response to tadalafil. Urol J; Fall;6(4):267-71, 2009.
• Savas M, Yeni E, Ciftci H, et al. Is Penile Length a Factor in Treatment of Erectile Dysfunction with PDE-5 Inhibitor? J Androl; 30:515-19, 2009.
• Lue TF. Erectile dysfunction. N Engl J Med ;342:1802- 1813, 2000.
• Kulkarni SS, Patil CS. Phosphodiesterase 5 enzyme and its inhibitors: update on pharmacological and therapeuti- cal aspects. Methods Find Exp Clin Pharmacol; 26: 789-99, 2004.
• Dogrell SA. Comparison of clinical trials with sildena- fil, vardenafil and tadalafil in erectile dysfunction. Expert Opinion; 6: 75-84, 2005.
• Rosen RC, Riley A, Wagner G, et al. The international in- dex of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology; 49:822–30, 1997.
• Wespes E, Amar E, Hatzichristou D, et al. EAU guidelines on erectile dysfunction: an update. Eur Urol; 49:806-815, 2006.
• Montague DK, Jarow JP, Brodercik GA, et al. Chapter 1: The management of erectile dysfunction: an AUA update. J Urol ;174:230-39, 2005.
• Carson CC. Erectile dysfunction: Evaluation and new tre- atment options. Psychosomatic Medicine; 66: 664-71, 2004.
• Gresser U, Gleiter CH. Erectile dysfunction: Comparison of efficacy and side effects of the PDE-5 inhibitors silde- nafil, vardenafil and tadalafil review of the literature. Eur J Med Res; 7:435-46, 2002.
• Montorsi F, Salonia A, Deho F, et al. Pharmacological ma- nagement of erectile dysfunction. BJU Int; 91: 446-54, 2003.
• Brock G, Nehra A, Lipshultz LI, et al. Safety and effı- cacy of vardenafıl for the treatment of men with erectile dysfunction after radical retropubic prostatectomy. J Urol; 170:1278-83, 2003.
• Montorsi F, Verheyden B, Meuleman E, et al. Long-term safety and tolerability of tadalafıl in the treatment of erecti- le dysfunction. Eur Urol; 45:339-45, 2004.
• Potempa AJ, Ulbrich E, Bernard I, et al. Effıcacy of varde- nafıl in men with erectile dysfunction:a flexible-dose com- munity practice study. Eur Urol; 46:73-79, 2004.
• Raina R, Lakin MM, Aganval A, et al. Effıcacy and factors associated with successful outcome of sildenafıl citrate use for erectile dysfunction after radical prostatectomy. Uro- logy; 63:960-66, 2004.
• Jackson G, Kloner RA, Costigan TM, et al. Update on cli- nical trials of tadalafil demonstrates no increased risk of cardiovascular adverse events. J Sex Med; 1: 161-67, 2004.
• Boztosun B, Olcay A, Değertekin M. Cinsel aktivite ve kar- diyovasküler risk. Anadolu Kardiyol Derg; 7: 423-6, 2007.
• Kloner RA. Cardiovascular effects of the 3 phosphodies- terase-5 inhibitors approved for the treatment of erectile dysfunction. Circulation; 110: 3149-55, 2004.
• Cheitlin MD, Hutter AM Jr, Brindis RG, et al. ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/American Heart Association. J Am Coll Cardi- ol; 33: 273-82, 1999.
• Simonsen U. Interactions between drugs for erectile dysfunction and drugs for cardiovascular disease. Int J Im- pot Res; 14: 178-88, 2002.
• Alboni P, Bettiol K, Fuca G, et al. Sexual activity with and without the use of sildenafil: risk of cardiovascular events in patients with heart disease. Ital Heart J; May; 5: 343-9, 2004.
• Kekilli M, Beyazit Y, Purnak T, et al. Acute myocardial in- farction after sildenafil citrate ingestion. Ann Pharmacot- her; 39: 1362-4, 2005.
• Kontaras K, Varnavas V, Kyriakides ZS. Does sildenafil ca- use myocardial infarction or sudden cardiac death? Am J Cardiovasc Drugs; 8(1):1-7, 2008.
• Akkus E, Kadioglu A, Esen A, et al. Turkish Erectile Dysfunction Prevalence Study Group, Prevalence and cor- relates of erectile dysfunction in Turkey: A population ba- sed study. Eur Urol; 41:298–304, 2002.
• http://www.turkstat.gov.tr/PreTablo.do?tb_id=37&ust_ id=11.
• Bayraktar Z, Atun Aİ. Erektil Disfonksiyonlu Türk Erkek- lerinin Üroloji Kliniklerine Müracaat Etmeme Gerekçele- ri. 9. Ulusal Androloji Kongresi, 1-4 Haziran, Mersin, pos- ter no:19, 2011.
• Karaköse A, Alp T, Güner ND, et al. The place of androlo- gical cases in our general urology practice. Turkish J Urol; 36(1):49-54, 2010.